Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -49.83% is 25% above its 5-year average of -66.65%, near the high end of its 5-year range (-297.38%–9.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.95% below its 12-month average of -34.62%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): -49.83%.
RETURN ON INVESTED CAPITAL (ROIC)
-49.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-34.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-67.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-66.65%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-53.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-43.95%
CURRENT VS 3Y AVG
+26.37%
CURRENT VS 5Y AVG
+25.23%
CURRENT VS 10Y AVG
+6.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-39.80%
vs the sector median at left
Neuphoria Therapeutics Inc.
Market Cap
$18.62M
Return on Invested Capital (ROIC)
-49.83%
TTM Avg
-34.62%
3Y Avg
-67.68%
5Y Avg
-66.65%
Market Cap
$17.32M
Return on Invested Capital (ROIC)
-46.69%
TTM Avg
-40.71%
3Y Avg
-34.73%
5Y Avg
-24.39%
Market Cap
$19.28M
Return on Invested Capital (ROIC)
-1489.99%
TTM Avg
-2573.36%
3Y Avg
-1757.31%
5Y Avg
-1757.31%
Market Cap
$18.18M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-171.06%
3Y Avg
-106.73%
5Y Avg
-106.73%
Market Cap
$17.46M
Return on Invested Capital (ROIC)
-51.68%
TTM Avg
-130.81%
3Y Avg
-134.17%
5Y Avg
-120.84%
Market Cap
$17.23M
Return on Invested Capital (ROIC)
-73.92%
TTM Avg
-122.57%
3Y Avg
-184.65%
5Y Avg
-161.38%
Market Cap
$17.19M
Return on Invested Capital (ROIC)
-57.74%
TTM Avg
-38.37%
3Y Avg
-49.64%
5Y Avg
-45.59%
Market Cap
$17.14M
Return on Invested Capital (ROIC)
-125.44%
TTM Avg
-125.44%
3Y Avg
-1118.57%
5Y Avg
-719.84%
Market Cap
$20.16M
Return on Invested Capital (ROIC)
-27.14%
TTM Avg
-181.80%
3Y Avg
-158.13%
5Y Avg
-129.64%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.62M | -49.83% | -34.62% | -67.68% | -66.65% |
| Cosmos Health Inc. (COSM)vs › | $17.32M | -46.69% | -40.71% | -34.73% | -24.39% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.28M | -1489.99% | -2573.36% | -1757.31% | -1757.31% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.18M | N/A | -171.06% | -106.73% | -106.73% |
| P3 Health Partners Inc. (PIII)vs › | $17.46M | -51.68% | -130.81% | -134.17% | -120.84% |
| PAVmed Inc. (PAVM)vs › | $17.23M | -73.92% | -122.57% | -184.65% | -161.38% |
| Lipocine Inc. (LPCN)vs › | $17.19M | -57.74% | -38.37% | -49.64% | -45.59% |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | -125.44% | -125.44% | -1118.57% | -719.84% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.16M | -27.14% | -181.80% | -158.13% | -129.64% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | -88.07% | -68.32% | -78.67% | -76.64% |
ROIC
-49.8%
ROE
-75.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -49.83% |
| 2026-03-31 | -72.50% |
| 2025-12-31 | -32.37% |
| 2025-09-30 | -19.89% |
| 2025-06-30 | 1.50% |
| 2025-03-31 | 9.38% |
| 2024-12-31 | -80.50% |
| 2024-09-30 | -108.46% |
| 2024-06-30 | -113.75% |
| 2023-12-31 | -153.61% |
| 2023-09-30 | -297.38% |
| 2023-06-30 | -124.41% |
| 2023-03-31 | -102.25% |
| 2022-12-31 | -101.19% |
| 2022-09-30 | -67.45% |
| 2022-06-30 | -65.30% |
| 2022-03-31 | -57.08% |
| 2021-12-31 | -61.63% |
| 2021-09-30 | -35.67% |
| 2021-06-30 | -31.30% |
| 2021-03-31 | -25.79% |
| 2020-12-31 | -26.79% |
| 2020-09-30 | -27.65% |
| 2020-06-30 | -22.03% |
| 2020-03-31 | -36.00% |
| 2019-12-31 | 2.19% |
| 2019-09-30 | -24.11% |
| 2019-06-30 | -52.74% |
| 2019-03-31 | -51.53% |
| 2018-12-31 | -119.74% |
| 2018-09-30 | -51.49% |
| 2018-06-30 | -73.83% |
| 2018-03-31 | -40.01% |
| 2017-12-31 | -27.79% |
| 2017-09-30 | -44.44% |
| 2017-06-30 | -48.14% |
| 2017-03-31 | -43.45% |
| 2016-12-31 | -78.33% |
| 2016-09-30 | -53.68% |
| 2016-06-30 | -67.32% |
| 2016-03-31 | -50.15% |
| 2015-12-31 | -71.94% |
| 2015-09-30 | -53.74% |
| 2015-06-30 | -87.94% |
| 2015-03-31 | -45.66% |
